Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Europe | Policy/Regulation | Value of Information | State-Transition | Infectious Diseases | Economics/Finance | North America -
Online LearningVideo, Teaching Resource 2020Valuing Statistical Lives: Concepts, Current Practices, and Challenges
Many policies aim to improve longevity, decreasing the risk of death in each year, and …
Many policies aim to improve longevity, decreasing the risk of death in each year, and the value of these risk reductions often dominate the estimated benefits of risk regulations and other policies. This value is often expressed as the value per statistical life (VSL), a term that is widely misunderstood. It is not the value that the analyst, the government, or the individual places on saving an identified life with certainty. Instead, it reflects individuals’…
Benefit-Cost Analysis | Global | Policy/Regulation | Climate/Environment | Health/Medicine -
ArticlePublication 2018Applications of ECEA Methodology in DCP3
Extended cost-effectiveness analyses (ECEAs) build on cost-effectiveness analyses (CEAs) by assessing consequences in both the …
Extended cost-effectiveness analyses (ECEAs) build on cost-effectiveness analyses (CEAs) by assessing consequences in both the health and non-health domains. The ECEA approach proves novel in that it includes equity and non-health benefits (FRP) in the economic evaluation of health policies, which enables multiple criteria to factor in the decision-making process. More important, the ECEA approach enables the design of benefits packages, such as essential universal health care and the highest-priority package, based on the quantitative…
Global | Global Governance | Priority Setting/Ethics | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Health/Medicine -
ArticlePublication 2018Consequences of a Cigarette Price Increase in 13 Middle Income Countries
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in …
This study used extended cost-effectiveness analysis to examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection for men in 13 middle income countries. A 50% increase in cigarette prices would lead to about 450 million years of life gained across the 13 countries from smoking cessation, with half of these in China. Across all countries, men in the bottom income group would gain 6.7 times more…
Global | Policy/Regulation | Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health/Medicine -
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Global | Policy/Regulation | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Global | Policy/Regulation | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Benefit-Cost Analysis | Global | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Social Determinants | Environmental Health | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Health/Medicine | Military/Defense | Science/Technology | Critical Thinking/Analysis -
ReportPublication 2016DCP3: Reproductive, Maternal, Newborn, and Child Health
This report from the World Bank is the second volume of the Disease Control Priorities, …
This report from the World Bank is the second volume of the Disease Control Priorities, Third Edition (DCP3) series. It focuses primarily on maternal conditions, childhood illnesses, and malnutrition, addressing topics from maternal mortality and morbidity, to acute illness and undernutrition in children under five, to the transition to older childhood and the illnesses that accompany this transition. The Disease Control Priorities Network (DCP) promotes and supports the use of economic evaluation for priority setting…
Global | Global Governance | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Economics/Finance | Health/Medicine -
ReportPublication 2017DCP3: Child and Adolescent Health and Development
This report from the World Bank is the eighth volume of the Disease Control Priorities, …
This report from the World Bank is the eighth volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on the health and well-being of children and adolescents, ages 5 to 21, worldwide. It provides estimates of mortality and morbidity among youth, examines the impact of interventions during that period on health and development, features successful community- and school-based health and nutrition interventions, reports on platforms that promote early childhood development, and highlights…
Global | Global Governance | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Child/Nutrition | Social Determinants | Economics/Finance | Health/Medicine